Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 2:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immunosuppression Clear all
Completed Phase 2 Interventional Results available

Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys

NCT00001984
View directory record Official record
Conditions
Graft Rejection, Kidney Disease
Interventions
Alemtuzumab and DSG
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Sep 26, 2026, 2:43 AM EDT
Not listed Not applicable Interventional

Immunosuppression Management in Renal Transplant Recipients With Transplant Excellence Based on TruGraf Test

NCT04670926
View directory record Official record
Conditions
Kidney Transplant Rejection, Immunosuppression
Interventions
TruGraf, Standard of Care
Diagnostic Test · Other
Lead sponsor
Transplant Genomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Sep 26, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine

NCT03527238
View directory record Official record
Conditions
Liver Transplant, Kidney Transplant
Interventions
PPM-based Computation Assisted Drug Dosing, Tacrolimus
Other · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Los Angeles, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Sep 26, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration

NCT00304954
View directory record Official record
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
Intravenous Daclizumab, Intravenous Infliximab, Observation, Oral Rapamycin
Drug · Other
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 92 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Sep 26, 2026, 2:43 AM EDT
Completed Phase 4 Interventional Results available

Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients

NCT02953873
View directory record Official record
Conditions
Immunosuppression
Interventions
Tacrolimus Extended Release Capsule, Mycophenolate mofetil, Prednisone, Mycophenolate Sodium
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Sep 26, 2026, 2:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients

NCT03437577
View directory record Official record
Conditions
Kidney Transplant Failure and Rejection
Interventions
immediate-release tacrolimus, extended release tacrolimus
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Sep 26, 2026, 2:43 AM EDT
Completed Phase 2 Interventional

SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant

NCT00002657
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bleomycin sulfate, recombinant interferon alfa, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, methotrexate, prednisone, vincristine sulfate, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
15 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2011
U.S. locations
86
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 26, 2026, 2:43 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction

NCT02474199
View directory record Official record
Conditions
Liver Transplant Recipient, Living Donor (of the Respective Liver Transplant Recipient)
Interventions
darTregs, Acetaminophen, Diphenhydramine, Immunosuppression (IS) Withdrawal, Study Mandated Procedures
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Sep 26, 2026, 2:43 AM EDT
Completed Not applicable Interventional Results available

Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients

NCT02954198
View directory record Official record
Conditions
Immunosuppression
Interventions
Tacrolimus, Prednisone, Mycophenolate mofetil, Everolimus
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Sep 26, 2026, 2:43 AM EDT
Recruiting Phase 2 Interventional

Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis

NCT07572383
View directory record Official record
Conditions
Interstitial Lung Disease, Pulmonary Fibrosis
Interventions
[68Ga]CBP8, Gadoterate Meglumine
Drug
Lead sponsor
Peter Caravan
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 26, 2026, 2:43 AM EDT
Terminated Not applicable Interventional Results available

Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation

NCT01230502
View directory record Official record
Conditions
Liver Transplant
Interventions
Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy, data and sample collection
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Sep 26, 2026, 2:43 AM EDT
Completed Phase 2 Interventional

Solitary Islet Transplantation for Type 1 Diabetes Mellitus Using Steroid Sparing Immunosuppression

NCT00006505
View directory record Official record
Conditions
Diabetes Mellitus Type 1
Interventions
Islet Transplantation
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Sep 26, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia

NCT00229619
View directory record Official record
Conditions
Anemia, Aplastic, Red-Cell Aplasia, Pure, Anemia, Diamond-Blackfan
Interventions
Rituximab
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Sep 26, 2026, 2:43 AM EDT
Completed Not applicable Interventional Results available

Intervention to Improve Adherence in Teen Kidney Transplant

NCT01356277
View directory record Official record
Conditions
Kidney Transplantation, Medication Adherence
Interventions
Action-focused problem-solving, Electronic pillbox monitoring, dose reminders, and feedback
Behavioral · Device
Lead sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Other
Eligibility
11 Years to 24 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
St Louis, Missouri • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 26, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

Islet Transplantation for Type 1 Diabetes

NCT00014911
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent
Interventions
Islet Transplantation, Sirolimus, Tacrolimus, Daclizumab, Sulfamethoxazole, Ganciclovir, Trimethoprim, Pentamidine
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
5
States / cities
Miami, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 26, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients

NCT00282256
View directory record Official record
Conditions
Liver Transplantation
Interventions
tacrolimus modified release (MR), tacrolimus
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
Up to 12 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Atlanta, Georgia • Indianapolis, Indiana • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2013 · Synced Sep 26, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation

NCT02533180
View directory record Official record
Conditions
Liver Transplant, Liver Transplantation
Interventions
Immunosuppression withdrawal
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
7
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Sep 26, 2026, 2:43 AM EDT
Recruiting Phase 2 Interventional

Early Signals of the Transition From Immune Quiescence to Activation in the Liver Allograft Microenvironment and in the Circulation

NCT07549503
View directory record Official record
Conditions
Liver Transplant
Interventions
Immunosuppression Reduction
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 13 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
10
States / cities
San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 26, 2026, 2:43 AM EDT
Completed Phase 4 Interventional Results available

Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients

NCT00113269
View directory record Official record
Conditions
Kidney Transplantation
Interventions
basiliximab, rabbit anti-thymocyte globulin, tacrolimus, alemtuzumab, mycophenolate mofetil, steroids
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2011 · Synced Sep 26, 2026, 2:43 AM EDT
Completed No phase listed Observational

Renal Transplantation With Immune Monitoring

NCT00419575
View directory record Official record
Conditions
Renal Transplantation, Immunosuppression
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 4, 2008 · Synced Sep 26, 2026, 2:43 AM EDT
Completed Phase 1 Interventional

Daclizumab to Treat HIV-Infected Patients

NCT00080431
View directory record Official record
Conditions
HIV Infections
Interventions
Daclizumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 26, 2026, 2:43 AM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV

NCT00001034
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections, Gastrointestinal Diseases
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • Wilmington, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 26, 2026, 2:43 AM EDT
Completed Phase 2 Interventional

Combination Therapy of Severe Aplastic Anemia

NCT00001964
View directory record Official record
Conditions
Severe Aplastic Anemia
Interventions
Cyclosporine A, ATG, MMF
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Year to 99 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Sep 26, 2026, 2:43 AM EDT
Active, not recruiting Phase 4 Interventional

Envarsus XR® in Adolescent Renal Transplant Recipients

NCT03266393
View directory record Official record
Conditions
Kidney Transplantation, Renal Transplantation, Grafting, Kidney
Interventions
Envarsus XR, Tacrolimus
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 20 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 26, 2026, 2:43 AM EDT